Skip to main content

Study Compares Rivaroxaban, Warfarin With Apixaban for Cirrhosis, A-Fib

Medically reviewed by Carmen Pope, BPharm. Last updated on July 9, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 8, 2024 -- For patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiators of rivaroxaban or warfarin versus apixaban have significantly higher rates of major hemorrhage, according to a study published online July 9 in the Annals of Internal Medicine.

Tracey G. Simon, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues compared the effectiveness and safety of apixaban versus rivaroxaban and versus warfarin in a population-based propensity score-matched cohort study involving patients with cirrhosis and AF.

The researchers found that compared with apixaban initiators, rivaroxaban initiators had significantly higher rates of major hemorrhagic events (rate difference, 33.1 per 1,000 person-years; hazard ratio, 1.47); no significant differences were seen in the rates of ischemic events or death. Across subgroup and sensitivity analyses, the rates of major hemorrhage were consistently higher. Compared with apixaban initiators, warfarin initiators also had significantly higher rates of major hemorrhage (rate difference, 26.1 per 1,000 person-years; hazard ratio, 1.38), especially hemorrhagic stroke (rate difference, 9.7 per 1,000 person years; hazard ratio, 2.85).

"These findings suggest apixaban may offer safety benefits over both rivaroxaban and warfarin in patients with cirrhosis and AF engaged in routine clinical care," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2024

Read this next

Real-Time AI-Driven Decision Support Aids Catheter Ablation

WEDNESDAY, May 7, 2025 -- An artificial intelligence (AI)-driven model can significantly improve procedural safety in cardiac electrophysiology with real-time decision support...

Faster Walking Pace Cuts Risk for Cardiac Arrhythmias

FRIDAY, April 25, 2025 -- Average and brisk walking pace are associated with a decreased risk for cardiac arrhythmias, according to a study published online April 15 in...

Most Patients Newly Diagnosed With A-Fib Do Not Receive Anticoagulants

WEDNESDAY, April 23, 2025 -- For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed anticoagulants in the year...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.